SL
NWBO

Sentinus LLC’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Sentinus LLC’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,925
Closed -$3.55K – 210
2024
Q4 		$3.55K Buy
+12,925
New +$3.55K ﹤0.01% 182
2024
Q3 		– Sell
-12,925
Closed -$5.52K – 197
2024
Q2 		$5.52K Buy
+12,925
New +$5.52K ﹤0.01% 182
2023
Q2 		$1.4M Buy
2,469,440
+279,000
+13% +$158K 0.44% 42
2023
Q1 		$1.37M Buy
2,190,440
+395,650
+22% +$247K 0.46% 46
2022
Q4 		$1.45M Buy
1,794,790
+600,375
+50% +$484K 0.85% 30
2022
Q3 		$1.02M Buy
+1,194,415
New +$1.02M 0.64% 36

Other funds holding NWBO

MSAM
Moloney Securities Asset Management Manchester, Missouri $840M AUM 18.11% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
EFG
Ethos Financial Group King Of Prussia, Pennsylvania $1.5B AUM 22.75% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.86B AUM 22.16% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $604M AUM 64.38% 1-Year Est. Return

Sentinus LLC's NWBO Position: Q1 2025 in Review

Sentinus LLC sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2025, closing a stake of 12,925 shares — an estimated $3.55K sold.

Sentinus LLC first reported a position in NWBO in Q3 2022 and held it in 6 quarters. The position peaked at $1.45M in Q4 2022. 8 funds tracked by Wall St. Rank hold NWBO as of Q1 2025.

  • Sentinus LLC reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2025 after selling out during the quarter.
  • Sentinus LLC sold 12,925 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2025, an estimated $3.55K.
  • Sentinus LLC first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2022 and held it in 6 quarters.
  • Sentinus LLC's Northwest Biotherapeutics, Inc. Common stock position peaked at $1.45M in Q4 2022.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2025.

Based on Sentinus LLC's 13F filing for Q1 2025, filed 15 May 2025.